Abstract Intermittent dosing for pre-exposure prophylaxis (PrEP) has been proposed as an alternative to daily PrEP to reduce cost and patient drug exposure and to improve adherence. One possible dosing regimen is preintercourse PrEP, which requires anticipating sex in advance. We examined preferences for daily versus preintercourse PrEP and ability to anticipate sex among 310 HIV uninfected members of HIV serodiscordant heterosexual couples in Thika, Kenya, with high HIV knowledge and experience with daily PrEP use in a clinical trial setting. Preferences were evenly split between daily PrEP (47.4 %) and pre-intercourse PrEP (50.7 %). Participants were more likely to prefer daily PrEP if they reported unprotected sex during the prior month (adjusted prevalence ratio [aPR] 1.48, 95 % CI 1.20-1.81) or \80 % adherence to study drug (aPR 1.50, 95 % CI 1.25-1.79), and were less likely to prefer daily PrEP if sex was usually planned, versus spontaneous (aPR 0.76, 95 % CI 0.61-0.96). A minority (24.2 %) reported anticipating sex [3 h in advance, with younger participants being less likely to do so (aPR 0.43, 95 % CI 0.23-0.83 for ages 18-29 vs. C40). Findings suggest that intermittent PrEP could be a popular option in this population, but that optimal adherence and sufficient drug levels might be challenging with a pre-intercourse regimen.
Introduction
Pre-exposure prophylaxis (PrEP) is a promising new strategy for the prevention of HIV infection. Clinical trials have demonstrated that oral tenofovir (TDF) and combination emtricitabine/tenofovir (FTC/TDF), when taken daily, are effective for HIV prevention in several populations, including heterosexual men and women [1, 2] , men who have sex with men (MSM) [3] , and injection drug users [4] . However, the effectiveness of PrEP depends strongly on participant adherence. In two clinical trials that did not demonstrate PrEP efficacy [5, 6] , low adherence is the leading hypothesis to explain the lack of HIV protection [7] .
Intermittent PrEP (iPrEP) has been proposed as an alternative to daily PrEP to reduce cost, toxicity, and patient burden and to improve adherence among those who find daily pill-taking challenging or unacceptable [8, 9] . Optimal iPrEP dosing approaches are under investigation for both adherence and pharmacologic characteristics; proposed regimens include a fixed dose several days per week, event-dependent dosing (e.g. before and/or after sexual intercourse), or some combination thereof. Oral iPrEP has been efficacious in animal models [9, 10] and is currently being evaluated in studies among MSM and heterosexual men and women comparing FTC/TDF in fixed and event-dependent dosing strategies [11] [12] [13] [14] . Topical iPrEP, using 1 % tenofovir gel, was found effective in reducing HIV risk in women, using a strategy of one pre-intercourse dose within 12 h before sex and one postintercourse dose within 12 h after sex [15] .
Acceptability studies, conducted largely in MSM, have found that preferences for daily versus intermittent oral PrEP varied across settings [13, 16, 17] . One study in African HIV serodiscordant couples found that both daily and intermittent PrEP were highly acceptable to participants [14] , but studies have not evaluated preferences for dosing regimens in heterosexual couples [18] . Adherence to pre-intercourse dosing will require the ability to anticipate sex far enough in advance to achieve active antiretroviral metabolites in genital tissues at levels adequate for protection. Only a few studies have evaluated sex planning, primarily among MSM, and results indicated that a high proportion of sex acts are not planned in advance [19] [20] [21] [22] .
Data about the ability to anticipate sex and the feasibility of oral iPrEP are needed to define iPrEP research priorities and to guide oral PrEP implementation, especially among HIV serodiscordant couples, who are a priority population for PrEP [18] . In sub-Saharan Africa, the region with the highest burden of HIV, up to 50 % of all HIV infected individuals are engaged in a stable HIV serodiscordant relationship [23] . Universal access to antiretroviral therapy (ART) is recommended by the World Health Organization (WHO) for HIV infected members of HIV serodiscordant couples to prevent transmission to their uninfected partners [24] . However, not all countries have adopted these guidelines, and some HIV infected individuals may be unwilling to initiate ART before they need it for their own health [25, 26] . In this context, PrEP could be used by HIV uninfected members of HIV serodiscordant couples when their HIV infected partners delay, decline or are not yet eligible for ART, from the time of initiation until viral suppression is reached, and in couples with ongoing additional risk even in the context of suppressive therapy (e.g., conception attempts, outside partners) [7] . We examined preferences for daily versus pre-intercourse PrEP dosing regimens and feasibility of pre-intercourse PrEP in a cohort of HIV serodiscordant couples participating in a daily oral PrEP efficacy trial in Kenya.
Methods

Study Design
Data for this cross-sectional study were collected between March and July 2011 from a convenience sample of HIV uninfected participants attending the Thika, Kenya site for the Partners PrEP Study, a randomized, double-blind, placebo-controlled clinical trial of daily oral TDF and FTC/ TDF PrEP to prevent HIV acquisition by uninfected members of heterosexual HIV serodiscordant couples. Detailed procedures for the clinical trial have been described elsewhere [1, 27] . Participants were aware of the primary results of the iPrEx study [3] on the efficacy of PrEP for HIV prevention. They were not aware of the secondary results on how the number of doses per week correlated with efficacy, which were published after the survey was completed [28] .
Participants
All participants at the Thika, Kenya study site who were currently enrolled and HIV uninfected at the time of the sub-study were eligible to participate; 405 out of 491 were enrolled in the sub-study (82 %). Of the 86 who did not participate, 50 were invited and declined, while 36 did not attend a study visit while the survey was being conducted. At an interim review in July 2011, the Partners PrEP Study independent Data and Safety Monitoring Board recommended that the placebo arm of the trial be discontinued early due to clear demonstration of PrEP efficacy for HIV prevention [1] . Participants were excluded from this analysis if they completed the survey after the announcement of PrEP efficacy in this population (n = 38) or if they were no longer in a couple with their study partner at the time of the survey (n = 57).
Study Procedures
For this sub-study, during a routine clinical trial visit, HIV uninfected participants were invited to answer a staffadministered survey about HIV prevention preferences, including PrEP and ART use by their HIV infected partner [25] . The survey consisted of 35 questions and was administered in Kiswahili, Kikuyu, or English, according to the participant's choice. To assess PrEP dosing preferences, participants were informed that pre-intercourse use would require knowing when they were going to have sex ''a few hours'' in advance, with no specific timeframe given. Participants were then asked: ''If PrEP works, would you rather take PrEP every day, or only before you have sex?'' and were also asked to provide reasons for their preference. Participants could cite multiple reasons, and interviewers coded each reason into pre-determined response categories. As a preliminary assessment of the feasibility of pre-intercourse PrEP in this population, participants were also asked how many hours in advance they were ''usually'' able to anticipate sex. Answer choices were categorical, with options of less than 1 h, 1-3, 3-6, 6-12, and more than 12 h. A cut-off of at least 3 h in advance was chosen for this analysis based on evidence that tenofovir reaches detectable levels in the male and female genital tracts 2-4 h after ingestion [29, 30] . Potential correlates of dosing preferences and anticipation of sex were assessed either at the study visit in which the interview was administered, or at study screening (for demographic variables). These correlates included age, sex, relationship duration, number of children, desire for more children, contraceptive use (women only), number of sex acts with the study partner in the prior month, report of any unprotected sex in the prior month, number of sexual partners besides the study partner in the prior month, whether sex was usually planned or spontaneous, willingness to pay for PrEP, and adherence to study drug (TDF, FTC/TDF, or placebo) in the prior month, as measured by pill count. CD4 counts were measured for the HIV infected partners at enrollment and every 6 months, and WHO stage and ART status were assessed quarterly. If the cross-sectional survey was completed at a visit that did not correspond with these measurements, we carried forward the values from the most recent visit at which they were measured.
Participants were interviewed individually and written informed consent was obtained separately for the clinical trial and for this site-specific sub-study. The study protocols were approved by the institutional review boards of the University of Washington and Kenyatta National Hospital.
Data Analysis
We calculated descriptive statistics for PrEP dosing preference, anticipation of sex, and other participant characteristics, stratified by gender. Univariate and multivariate log binomial regression methods with robust standard errors were used to examine correlates of preferring a daily PrEP dosing regimen (vs. pre-intercourse PrEP) and correlates of anticipating sex at least 3 h in advance (vs. less than 3 h). The log binomial model directly estimates prevalence ratios, which are preferable to odds ratios when the prevalence of the outcome measure is not rare (i.e. greater than 10 %) [31] . Each multivariate model included all factors significantly associated with the outcome at a level of p \ 0.10 in the univariate analysis. To obtain convergence of the multivariate model for PrEP regimen preference, we used Wacholder's method of truncating estimates to values slightly less than 1.0 [32] . All analyses were conducted using Stata/MP version 12.1 (StataCorp LP, College Station, TX, USA).
Results
Population Characteristics
Data from 310 HIV uninfected participants were included in this analysis. The sample was predominantly male (78.4 %, Table 1 ), consistent with the proportion of couples with an HIV uninfected male partner enrolled in the parent study overall (62 %) [27] and at the Thika site (77.2 %) [25] . At the time of enrollment into the Partners PrEP Study, participants had a median age of 34.1 years (interquartile range [IQR] 29.1-40.8) and the median partnership duration was 5.1 and 10.9 years for couples with HIV uninfected males and females, respectively. At the time of the survey, participants had been followed in the Partners PrEP Study for a median of 21 months (IQR 15-27), the participants' HIV infected partners had a median CD4 count of 503 cells/mm 3 (IQR 378-704), and 62.9 % were not yet eligible for ART according to the 2011 Kenyan guidelines of CD4 count \350 cells/lL or WHO HIV disease stage 3 or 4. Participants reported a median of 4 sex acts with their study partner in the prior month (IQR 3-8), and very few participants (2.6 %) reported sexual partners in addition to their study partner in the prior month. About 85 % of participants stated that they would be willing to pay for PrEP if it were effective. Among those willing to pay, participants reported that they could afford a median of 200 Kenyan Shillings (KSh) per month for PrEP (IQR 100-500), or about 2.20 USD. Over 87 % of participants had study drug adherence C80 %.
Preferences for Daily Versus Intermittent PrEP
Overall, 147 participants (47.4 %) preferred a daily PrEP regimen, 157 (50.7 %) preferred pre-intercourse PrEP, and 5 (1.6 %) did not have a preference (Table 1) . Among those who preferred daily PrEP, the most common reasons were that they believed it was more effective (74.2 %), that they were already used to taking PrEP daily (26.5 %), and that sex was not usually planned (15.7 %). Among those who preferred pre-intercourse PrEP, the most common reasons were lower pill burden (51.0 %), not having to take pills when sex was not anticipated (33.8 %), fewer side effects (26.1 %) and lower cost (14.7 %).
Correlates of PrEP Regimen Preferences
Participants were more likely to prefer a daily regimen if they reported unprotected sex with their study partner in the prior month (65.7 vs. 45.9 %, adjusted prevalence ratio [aPR] 1.48, 95 % confidence interval [CI] 1.20-1.81, Table 2 ), and were less likely to prefer a daily regimen if they reported that sex was usually planned rather than The following data were missing: Partnership duration in years (n = 6); HIV infected partner WHO stage (n = 4); Sex acts with study partner (n = 1); Any unprotected sex with study partner (n = 1); Had sexual partner(s) in addition to study partner (n = 1); Preferred PrEP regimen (n = 1) 
Correlates of Anticipating Sex at Least 3 h in Advance
Approximately one-quarter of participants (24.2 %) reported that they usually anticipated sex at least 3 h in advance. In multivariate analysis, younger participants were less likely to anticipate sex at least 3 h in advance (aPR 0.43, 95 % CI 0.23-0.83 for ages 18-29 vs. ages C40, Table 3 ). Although not statistically significant, women were less likely than men to anticipate sex in advance (aPR 0.60, 95 % CI 0.33-1.10, 15 vs. 27 %, respectively) and participants who reported more sex acts in the prior month were less likely to anticipate sex (aPR 0.57, 95 % CI 0.28-1.18 for [8 vs. 1-3 sex acts). Other factors, such as relationship duration, fertility desire, condom use, and the ART status of the participant's HIV infected partner, were not associated with anticipating sex at least 3 h in advance.
Discussion
In this population of HIV uninfected individuals in an HIV serodiscordant partnership who were already accustomed to daily pill taking and well-informed about HIV prevention, preferences were split between daily and intermittent PrEP dosing regimens. Participants were more likely to prefer a daily regimen if they reported unprotected sex in the prior month or that sex is usually spontaneous, or if they had low adherence to study drug. Although half of participants preferred pre-intercourse PrEP, only a quarter reported anticipating sex at least 3 h in advance, with younger participants being less likely to anticipate sex. Our findings on both regimen preferences and sex planning differ from studies of MSM, as might be expected based on differences in population, demographics, geography, and sexual behavior. In a study of substance-using MSM in the U.S., 90 % preferred daily PrEP because it could be easily incorporated with other daily medication regimens and there would be lower risk of missing doses while intoxicated [17] . In contrast, Kenyan MSM study participants generally preferred iPrEP, due to the lower pill burden, though participants also cited multiple adherence challenges, particularly to post-coital dosing [16] . In studies of MSM in the U.S. and Thailand, 42 and 65 % of participants, respectively, reported that sex was usually planned in advance [19, 20] . In another study conducted in the same population as our survey, participants correctly anticipated 61 % of sexual activity 1 day in advance [22] . Our results suggest that participants' HIV risk behavior, adherence behavior, and ability to anticipate sex all inform regimen preference. Although the Partners PrEP Study findings were unknown at the time of the survey, and no data are available on the effectiveness of oral iPrEP, a large proportion of participants believed that daily PrEP would be more effective in preventing HIV, and participants with higher risk behaviors in the prior month (i.e. unprotected sex) tended to prefer daily PrEP. In the entire Partners PrEP Study cohort, risk behavior was also associated with adherence to daily PrEP, with not having sex being the strongest single predictor of poor adherence [33] . Known risk, due to couple's mutually-disclosed HIV serodiscordant status, has been hypothesized as one reason for the high adherence to PrEP among HIV uninfected members of HIV serodiscordant couples [34, 35] . Our finding that participants with low adherence to the daily study drug regimen were more likely to prefer a daily regimen is unexpected. However, because we excluded participants no longer in a couple with their study partner, we may have excluded most participants who had low adherence due to sexual inactivity. Participants with low adherence in our sample may have preferred a daily regimen because they felt it would be easier to adhere to than an intermittent regimen, similar to the American substance-using MSM described above [17] .
Many participants in our study saw the ability to abstain from PrEP use when not sexually active as an advantage of intermittent dosing, and valued the potential opportunity to reduce their overall pill burden. Given that most study participants reported sex about 4 times per month (or approximately once per week), an intermittent regimen could reduce dosing requirements substantially. However, many participants also reported that sex is not usually planned, and those who did not plan sex were more likely to prefer a daily regimen. The low proportion of couples reporting planned sex implies that adherence to pre-intercourse dosing within a window to achieve adequate tissue concentrations of activated metabolites may be difficult. Small feasibility studies among MSM and HIV serodiscordant couples have found that adherence to oral fixed and post-intercourse intermittent regimens is lower than to daily regimens [13, 14] , suggesting that challenges may arise with any iPrEP regimen. If multiple PrEP regimens, including daily, fixed intermittent, pre-intercourse and/or post-intercourse PrEP, were rolled out for public use, counseling would need to help users periodically assess their level of HIV risk and their ability to adhere to various regimens, to select the most appropriate method for them at that time. This counseling could provide an opportunity to emphasize the costs, side effects, and efficacy of different dosing regimens, to tailor regimens to users' preferences and priorities. Current and planned PrEP trials and demonstration projects offer one opportunity to further explore messaging around PrEP delivery.
Our findings that younger people are less likely to anticipate sex are consistent with studies suggesting relationship differences among older versus younger couples, such as communication and control within relationships [36, 37] , among others, that could impact feasibility of iPrEP. While this suggests that younger people may have trouble adhering to pre-intercourse dosing strategies, these same underlying issues may also complicate adherence to daily PrEP, for example due to difficulty discussing HIV risk or concerns about stigma with PrEP use. Indeed, younger age was associated with poorer daily adherence in PrEP studies [6, 33] . Young adults are also at high risk of non-compliance for many other medication regimens, including contraception, ART and several chronic disease medications [38] [39] [40] [41] . Interventions found to improve adherence for these medications in youth may therefore be applicable to PrEP [38] . Although not statistically significant in multivariate analysis, we also found that women in our sample were less likely than men to anticipate sex. Many studies have illustrated that men have greater power within sexual relationships in this region [42, 43] , and may decide when sex will occur without communicating or negotiating with their partners. In this context, women may have greater trouble adhering to a pre-intercourse PrEP regimen than men.
There are several limitations to this study. While our sample is representative of the larger population of Partners PrEP Study participants [25, 27] , those who participated in the clinical trial and this survey may not be fully representative of HIV serodiscordant couples who would be targeted for PrEP use. Because the study participants had extensive experience with daily PrEP use, as well as extensive counseling on HIV prevention as part of the parent clinical trial, their opinions on daily use were well informed, and they were better able to consider scenarios about iPrEP. However, opinions on iPrEP are hypothetical, and preferences could change with actual use of iPrEP. In addition, the question on preferences did not specify whether iPrEP efficacy would be comparable to daily PrEP, and relative efficacy may also inform preferences. Due to the cross-sectional design, we were unable to assess how PrEP regimen preferences change over time or with changing sexual risk behaviors. Some potential correlates were self-reported, such as condom use and additional partnerships, and may be biased due to poor recall or social desirability. In an earlier study conducted among HIV serodiscordant couples, selfreported sexual risk behavior was strongly correlated with pregnancy incidence and risk of HIV infection, from both within and outside the partnership [44] [45] [46] [47] , suggesting that such reports have reasonable validity in this population.
The decision to use 3 h as a cut-off for considering sex as ''anticipated in advance'' in this analysis was based on pharmacokinetic (PK) data about tenofovir and emtricitabine metabolites in the genital tract after a single dose of oral FTC/TDF [29, 30] . However, this evidence comes from a small number of studies in HIV infected men and women, and the concentrations found in these genital tract samples may not have been high enough to actually prevent HIV infection should an exposure occur. Although the minimum effective intracellular concentration of tenofovir is unknown, a PBMC tenofovir diphosphate (TFV-DP) concentration of 16 fmol/million was estimated to provide 90 % protection for MSM in the iPrex study [28] . Recent PK studies suggest that concentrations of this level may only be attained 12-24 h after ingestion [48, 49] . Only 7 % of study participants reported that they could usually anticipate sex at least 12 h in advance, suggesting that intermittent dosing of PrEP 12-24 h before sex would be difficult in this population. However, there is limited data to establish the necessary genital concentrations of activated intracellular metabolites of TFV-DP and FTC triphosphate required for effective protection from HIV, and the threshold may differ by site of sexual exposure [49, 50] . More PK data are needed to estimate how far in advance PrEP must be taken to provide sufficient levels of protection and to guide the feasibility of pre-intercourse dosing in various populations.
To our knowledge, this study provides the first results on PrEP regimen preferences in HIV serodiscordant couples with high HIV knowledge and experience with daily PrEP use. Preferences for daily versus intermittent PrEP were evenly split, and preferences were strongly correlated with an individual's assessment of their risk behavior and their ability to use iPrEP appropriately, as well as with adherence to study drug. Sexual activity in this population was infrequent enough that iPrEP would significantly reduce drug exposure and pill burden. However, relatively few participants were able to anticipate sex in advance, indicating that pre-intercourse dosing might be challenging, especially among younger persons. In all oral PrEP studies, adherence to the daily regimen has proven challenging for a proportion of the population. A choice of PrEP dosing options might be available in the future, including daily PrEP as well as intermittent fixed dose, pre-intercourse, and/or post-intercourse regimens, depending on the results of ongoing and future studies. Such options would permit individuals to choose between different regimens to suit their personal preferences and changing sexual behavior patterns, similar to the way women choose a contraceptive method to suit their particular circumstances [51] . A variety of options for PrEP dosing, if efficacious for HIV prevention, might increase adherence and maximize the public health impact that this strategy can have on the HIV epidemic.
